“The people who pay for drugs aren’t fully buying those arguments — and want Sovaldi to back off its prices. They argue that Gilead could more than cover the costs of drug development and even run a profit with a lower price. This year alone, analysts expect Sovaldi to generate as much as $15 billion in sales. ‘This represents an abuse of market power,’ says John Rother, who runs the National Coalition on Health Care. His group announced Wednesday a new Campaign for Sustainable Rx Pricing, that will push specifically for Sovaldi to lower its prices. ‘We grant exclusive rights to companies to reward them for their innovation, but with that power comes great responsibility. Not just to the shareholders of the company, but to the broader society. ‘
Read More